Sagittarius Life Science - Asset Resilience Ratio
Sagittarius Life Science (3205) has an Asset Resilience Ratio of 60.84% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Sagittarius Life Science's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Sagittarius Life Science's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Sagittarius Life Science.
Liquid Assets Composition Over Time
This chart breaks down Sagittarius Life Science's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Sagittarius Life Science (3205) investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$652.00 Million | 60.84% |
| Total Liquid Assets | NT$652.00 Million | 60.84% |
Asset Resilience Insights
- Very High Liquidity: Sagittarius Life Science maintains exceptional liquid asset reserves at 60.84% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Sagittarius Life Science Industry Peers by Asset Resilience Ratio
Compare Sagittarius Life Science's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Sagittarius Life Science (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Sagittarius Life Science.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 60.84% | NT$652.00 Million ≈ $20.54 Million |
NT$1.07 Billion ≈ $33.76 Million |
+46.00pp |
| 2024-12-31 | 14.83% | NT$77.11 Million ≈ $2.43 Million |
NT$519.83 Million ≈ $16.38 Million |
+2.57pp |
| 2023-12-31 | 12.26% | NT$81.49 Million ≈ $2.57 Million |
NT$664.72 Million ≈ $20.94 Million |
-1.60pp |
| 2022-12-31 | 13.86% | NT$80.24 Million ≈ $2.53 Million |
NT$579.12 Million ≈ $18.25 Million |
-1.42pp |
| 2021-12-31 | 15.28% | NT$103.25 Million ≈ $3.25 Million |
NT$675.75 Million ≈ $21.29 Million |
+14.45pp |
| 2020-12-31 | 0.83% | NT$6.15 Million ≈ $193.76K |
NT$740.74 Million ≈ $23.34 Million |
+0.34pp |
| 2019-12-31 | 0.49% | NT$4.00 Million ≈ $126.02K |
NT$811.59 Million ≈ $25.57 Million |
-8.32pp |
| 2016-12-31 | 8.81% | NT$124.50 Million ≈ $3.92 Million |
NT$1.41 Billion ≈ $44.50 Million |
-- |
About Sagittarius Life Science
Sagittarius Life Science Corp engages in the research, development, and sale of Chinese and western medicines, and health food products in Taiwan and Asia. It also offers organic food, daily necessities, and pet food; and engages in the research and development of biotechnology. Sagittarius Life Science Corp was founded in 1998 and is based in Taipei, Taiwan.